Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03138525 · ClinicalTrials.gov registry record
Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 161
- Enrollment target
NCT03138525 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 161 participants.
The verdict
NCT03138525 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 161 participants
- Enrollment target
Study Summary
The purpose of this study is to assess effects of B cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before the infusions at 6 and 12 months. The effects on the immune system will be assessed by performing transcriptome profiling of immune cells, measuring serum levels of microRNAs, and analyzing serum autoantibody immune signatures using antigen arrays. In addition, blood will be collected once from a group of healthy individuals to serve as controls.
Interventions
- OTHER Blood sampling (MS)
- OTHER Blood sampling (controls)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 161 participants |
| Start Date | 2017-06-20 |
| Est. Completion | 2019-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03138525
The ClinicalTrials.gov registry entry for NCT03138525 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood sampling (MS) is the first listed.
NCT03138525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03138525 about?
NCT03138525 is a clinical study titled "Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis". The purpose of this study is to assess effects of B cell depletion on the immune system in patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will be done by collecting blood from patients starting treatment with ocrelizumab before the first infusion and before t...
What is the current status of trial NCT03138525?
This trial is currently completed. The enrollment target is 161 participants. The study started on 2017-06-20. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT03138525?
The interventions under investigation include: Blood sampling (MS) (OTHER), Blood sampling (controls) (OTHER).
Who is sponsoring clinical trial NCT03138525?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.